Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Primary Immunodeficiency
Do you alter therapy for GLILD from antimetabolite/rituximab to monotherapy if the biopsy is predominantly T or B cells?
Related Questions
What are the implications of checking post-vaccine titers after administration of Prevnar 20 compared to PPSV23?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
What testing would you pursue next in a pediatric patient with recurrent staph abscesses, negative Invitae PID panel and negative NCF1 gene testing, and 1/2 abnormal DHR test with 1 suggestive of p47 deficiency?
How would you treat autologous GVHD after a thymic transplant but with no thymopoeisis?
How exhaustive (especially considering cost) should an immunological workup be for patients with extensive, recurrent, or deep seated Staph aureus infections without obvious immunocompromise (e.g. cancer, diabetes, steroids) or recurrent breaks in skin integrity?
How do you recommend spacing dosing between immunoglobulin replacement and eculizmab administration?
Do you give additional pneumococcal vaccines after a dose of PCV20 in patients with asplenia?
What are the implications of immunosuppressive therapy in a chronic asymptomatic T cell lymphopenic adult undergoing lung transplant evaluation?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
When would you pursue genetic testing for severe recalcitrant atopic dermatitis?
